3. Evaluation of UA (urinalysis by dipstick), C BC (complete blood count with differential and platelet count), serum chemistries (electrolytes, AST, ALT, alkaline phosphatase, bilirubin, creatinine and blood urea nitrogen (BUN)). 4. Obtain 10 cc of peripheral blood for the evaluation of a pre -existent HER2 antibody response. 200cc peripheral blood to obtain PBMC for T -cell immunity studies. 5. Tetanus toxoid immunization. 76. Patients will have a CXR (PA and lateral) as well as an ECG to serve as baseline. (These tests will not be used to determine eligibility and will only be repeated should subjects develop pulmonary or cardiac medical problems during the course of study.) C. Monthly immunizations 1. Post immunization monitoring: The subjects will be observed for at least 60 minutes post immunizat ion. Vital signs and local reactions will be assessed by the staff before discharge and at least 60 minutes after vaccination. 2. Monthly vaccination for 6 months. Vaccinations will be administered i.d. on the upper arm. If a subject has undergone comp lete axillary node dissection the vaccine will be administered to the contralateral side. If the subject has undergone bilateral axillary node dissections, the vaccine will be administered on the anterior or lateral thigh. As much as possible each dose of vaccine will be administered within the same draining lymph node site. 3. UA, serum chemistry and CBC. 4. 210 cc blood draw prior to vaccine #3 to evaluate HER2 immune responses. D.